

Special Issue

Triggered Drug Delivery Strategies for Glioblastoma

Message from the Guest Editors

Glioblastoma presents extreme therapeutic challenges due to its infiltrative nature, dynamic tumor microenvironment, and limited drug accessibility across the blood-brain barrier. Stimuli-responsive drug delivery systems have emerged as powerful tools to address these limitations by enabling spatially and temporally controlled therapeutic release. This Special Issue focuses on advanced delivery platforms responsive to endogenous glioblastoma cues, such as redox gradients, enzymatic activity, acidic pH, and ionic dysregulation, as well as external triggers including ultrasound, photothermal and photodynamic activation, and magnetic fields. Emphasis is placed on systems integrating endogenous and exogenous stimuli to achieve synergistic, on-demand therapy with enhanced precision and reduced off-target toxicity. Original research and critical reviews covering material design, mechanistic insights, preclinical validation, and translational perspectives are encouraged.

Guest Editors

Dr. Maria Mendes

1. Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal
2. Coimbra Chemistry Centre, Institute of Molecular Sciences - IMS, University of Coimbra, Coimbra, Portugal

Dr. Mariana Magalhães

1. Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
2. INEB—Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal

Deadline for manuscript submissions

31 July 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/267909

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)